Novo Nordisk A/S (FRA:NOV)

Market Cap	246.57B
Revenue (ttm)	40.64B
Net Income (ttm)	14.02B
Shares Out	n/a
EPS (ttm)	3.15
PE Ratio	17.58
Forward PE	15.43
Dividend	1.53 (2.75%)
Ex-Dividend Date	Mar 28, 2025

Volume	59
Average Volume	563
Open	56.64
Previous Close	56.00
Day's Range	55.53 - 56.76
52-Week Range	50.95 - 125.36
Beta	n/a
RSI	34.29
Earnings Date	Aug 6, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NOV

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK